Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics
The South San Francisco-based CRISPR upstart that set out to develop diagnostics under co-founder Jennifer Doudna’s guidance is back with $45 million in funding — and new ambitions in therapeutics.
Mammoth Biosciences is also putting its tech to the test amid heightened vigilance surrounding the novel coronavirus emerging out of Wuhan, China. The goal is to prototype a rapid molecular test that can be used at point of care.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.